These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12811115)

  • 1. Look beyond budgets to the broader benefits.
    Dugal R; Mani A; Potvin K
    Healthc Pap; 2002; 3(1):77-82; discussion 87-94. PubMed ID: 12811115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Our advice? Get a budget!
    Brougham M; Metcalfe S; McNee W
    Healthc Pap; 2002; 3(1):83-5; discussion 87-94. PubMed ID: 12811116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing healthcare costs within an integrated framework.
    Fernandes R
    Healthc Pap; 2002; 3(1):70-6; discussion 87-94. PubMed ID: 12811114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More of the same is not enough.
    Willison DJ
    Healthc Pap; 2002; 3(1):47-55; discussion 87-94. PubMed ID: 12811111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The drug budget silo mentality: the French case.
    Le Pen C
    Value Health; 2003; 6 Suppl 1():S10-9. PubMed ID: 12846922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economics of prescription drug prices, government intervention, and the importation of drugs from Canada.
    Openshaw MS
    Nurs Econ; 2005; 23(6):307-11, 279. PubMed ID: 16459902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moving beyond the drug budget silo mentality in Europe.
    Drummond M; Jönsson B
    Value Health; 2003; 6 Suppl 1():S74-7. PubMed ID: 12846928
    [No Abstract]   [Full Text] [Related]  

  • 9. Getting the cat back in the bag: reforming the way provinces manage drug expenditures to make them manageable.
    Levy AR; Gagnon YM
    Healthc Pap; 2002; 3(1):32-7; discussion 87-94. PubMed ID: 12811108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using disease management and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany.
    Schwermann T; Greiner W; v d Schulenburg JM
    Value Health; 2003; 6 Suppl 1():S20-30. PubMed ID: 12846923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug prices: how they are established and existing price control systems.
    Rovira Forns J
    Salud Colect; 2015 Mar; 11(1):35-48. PubMed ID: 25853829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug policy: making effective drugs available without bankrupting the healthcare system.
    Laupacis A; Anderson G; O'Brien B
    Healthc Pap; 2002; 3(1):12-30. PubMed ID: 12811107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.
    Gleeson D; Lopert R; Reid P
    Health Policy; 2013 Oct; 112(3):227-33. PubMed ID: 23992756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The drug budget silo mentality: the Dutch case.
    Koopmanschap MA; Rutten FF
    Value Health; 2003; 6 Suppl 1():S46-51. PubMed ID: 12846925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does generic entry lower the prices paid for pharmaceuticals in Australia? A comparison before and after the introduction of the mandatory price-reduction policy.
    Spinks J; Chen G; Donovan L
    Aust Health Rev; 2013 Nov; 37(5):675-81. PubMed ID: 24160374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug policy: the challenge is to overcome fragmentation.
    McFarlance A
    Healthc Pap; 2002; 3(1):38-42: discussion 87-94. PubMed ID: 12811109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad, and the ugly ways.
    Inotai A; Kaló Z
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):627-632. PubMed ID: 31810392
    [No Abstract]   [Full Text] [Related]  

  • 18. The drug budget silo mentality in Europe: an overview.
    Garrison L; Towse A
    Value Health; 2003; 6 Suppl 1():S1-9. PubMed ID: 12846921
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug spending in Canada: recent trends and causes.
    Morgan S
    Med Care; 2004 Jul; 42(7):635-42. PubMed ID: 15213487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expenditures on medicines by the Rio de Janeiro Municipal Health Department, Brazil, 2002-2011].
    Silva RM; Caetano R
    Cad Saude Publica; 2014 Jun; 30(6):1207-18. PubMed ID: 25099044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.